Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dysport for Vocal Tics in Tourette's Syndrome
NCT02187679Unknown
- Sponsor
- Detroit Clinical Research Center
- Start
- Jan 2014
- Primary completion
- Jun 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of botulinum toxin type A in Tourette syndrome (TS) and persistent vocal tic disorder, sponsored by Detroit Clinical Research Center. Primary endpoint: Vocal Tic Reduction at 15 days. Status: unknown.
02
Drugs
botulinum toxin type A
03
Conditions
Tourette syndrome (TS)persistent vocal tic disorder
Beyond the preview
Go deeper on NCT02187679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02187679.